Go Back This article was viewed 53 times

Brief Commentary


The emerging role of CRISPR-Cas9 in molecular oncology

Radhika A. Vaishnav
Department of Biomedical Research, Harmony Clinic and Vadodara StrokeCenter,Vadodara,Gujarat,India
Corresponding Author:

Radhika A. Vaishnav

Department of Biomedical Research, Harmony Clinic and Vadodara StrokeCenter,Vadodara,Gujarat,India
E-mail: radhikavaishnav@gmail.com

Corresponding Author:

Radhika A. Vaishnav

Department of Biomedical Research, Harmony Clinic and Vadodara StrokeCenter,Vadodara,Gujarat,India
E-mail: radhikavaishnav@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20172641

ABSTRACT


It is not uncommon to be curious about the recent hype surrounding the new gene editing player, Cas9, which recognizes and holds into place DNA segments known as clustered regularly interspaced short palindromic repeats (CRISPR). Together, they are known as CRISPR-Cas9 or simply “CRISPR” for brevity. The binding of Cas9 causes the CRISPR sequences to become available for editing.
Keywords: CRISPR-Cas9, CRISPR, Molecular oncology